Skip to main content

Table 3 Use of antithrombotic drugs at diagnosis, overall and according to CHA2DS2-VASc scores of 0 or 1 and 2–9

From: International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Antiplatelet druga All patients (N = 5072) Patients with CHA2DS2-VASc score of 0 or 1 (N = 665) Patients with CHA2DS2-VASc score 2–9 (N = 4289)
Acetylsalicylic acid (Aspirin/ASA) 501 (9.9) 28 (4.2) 465 (10.8)
ADP receptor/P2Y12 inhibitor 248 (4.9) 13 (2.0) 231 (5.4)
Glycoprotein IIb/IIIa inhibitor 9 (0.2) 2 (0.3) 6 (0.1)
Prostaglandin analogue 71 (1.4) 5 (0.8) 66 (1.5)
Other antiplatelet 8 (0.2) 2 (0.3) 6 (0.1)
  1. aCategories are not mutually exclusive